J B Chemicals and Pharmaceuticals

1,571.60
+29.10
(1.89%)
Market Cap
24,466.20 Cr
EPS
35.66
PE Ratio
38.30
Dividend Yield
0.78 %
Industry
Healthcare
52 Week High
2,030.00
52 Week Low
1,385.75
PB Ratio
7.63
Debt to Equity
0.18
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+81.82 %
+81.82 %
Hold
Hold+9.09 %
+9.09 %
Sell
Sell+9.09 %
+9.09 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,687.55
#1 4,04,899.80
34.33
#1 49,887.20
12.06
#1 9,648
13.77
47.60
5,589.30
1,48,378.40
71.83
8,184.00
0.89
1,600
#1 64.53
47.92
1,463.05
1,18,158.10
23.68
26,520.70
14.17
4,155
47.38
50.89
3,129.00
1,05,899.60
56.84
10,785.70
11.59
1,656
13.54
45.29
2,350.50
96,976.60
47.52
10,615.60
19.57
1,942
-16.38
48.68
1,109.50
92,582.80
#1 17.23
28,905.40
12.36
5,578
1.69
40.66
1,969.25
89,904.30
31.34
20,141.50
#1 19.94
1,936
38.82
46.62
868.85
87,426.60
19.27
19,831.50
13.82
3,831
29.92
44.56
29,641.10
62,985.30
47.10
6,097.20
10.80
1,201
16.01
48.36
1,082.45
62,868.90
17.83
29,559.20
17.55
3,169
-10.04
41.61
Growth Rate
Revenue Growth
11.46 %
Net Income Growth
34.78 %
Cash Flow Change
27.97 %
ROE
14.34 %
ROCE
29.17 %
EBITDA Margin (Avg.)
18.76 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
408
444
398
435
459
475
445
447
545
452
604
554
619
613
605
627
786
811
796
767
902
889
852
878
1,010
1,011
972
Expenses
326
354
304
353
350
356
339
362
367
334
377
405
442
466
473
500
612
625
618
599
664
638
621
664
724
730
709
EBITDA
82
90
94
81
109
119
106
85
178
119
227
149
177
146
133
127
174
186
178
168
238
251
231
215
286
281
263
Operating Profit %
20 %
19 %
20 %
16 %
22 %
22 %
21 %
18 %
30 %
25 %
31 %
23 %
27 %
21 %
21 %
20 %
22 %
23 %
22 %
21 %
26 %
28 %
26 %
23 %
28 %
27 %
26 %
Depreciation
15
15
15
12
16
16
17
17
17
18
17
17
18
16
17
22
26
28
28
32
31
32
34
41
41
42
42
Interest
1
1
1
1
1
1
1
1
4
2
1
1
1
1
1
2
6
8
8
14
12
10
13
9
6
2
3
Profit Before Tax
66
75
78
68
92
102
88
67
157
99
209
132
158
129
114
103
142
150
141
123
194
209
184
165
240
237
218
Tax
21
23
28
22
30
8
22
17
38
25
54
31
39
32
30
18
37
39
35
35
52
58
50
38
63
62
56
Net Profit
46
52
50
47
62
94
66
50
120
74
154
101
119
98
84
85
105
111
106
88
142
151
134
126
177
175
163
EPS in ₹
5.46
6.14
6.07
5.68
7.73
11.67
8.26
6.30
15.45
9.55
19.94
13.02
15.38
12.65
10.85
10.98
13.59
14.37
13.72
11.33
9.20
9.72
8.62
8.22
11.39
11.24
10.46

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
1,487
1,648
1,674
1,765
1,792
1,821
2,238
2,607
3,554
3,994
Fixed Assets
329
440
679
640
621
651
634
1,277
1,901
2,004
Current Assets
901
816
795
1,047
1,051
1,073
1,553
1,253
1,528
1,853
Capital Work in Progress
55
135
4
17
15
16
26
19
55
76
Investments
367
479
411
434
457
403
678
13
206
388
Other Assets
737
594
580
674
699
750
901
1,299
1,392
1,525
Total Liabilities
1,487
1,648
1,674
1,765
1,792
1,821
2,238
2,607
3,554
3,994
Current Liabilities
460
431
281
275
244
313
345
384
554
868
Non Current Liabilities
33
31
27
46
65
69
79
85
519
203
Total Equity
995
1,186
1,366
1,444
1,483
1,438
1,813
2,139
2,480
2,923
Reserve & Surplus
978
1,167
1,347
1,425
1,464
1,420
1,794
2,119
2,465
2,908
Share Capital
17
17
17
17
16
16
16
16
16
16

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
13
15
-28
43
11
-6
-3
34
20
11
Investing Activities
-112
-26
-45
-21
-28
24
-231
2
-962
-404
Operating Activities
127
140
201
123
194
276
315
170
626
801
Financing Activities
-1
-100
-184
-60
-156
-306
-87
-138
357
-386

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
55.91 %
55.91 %
55.91 %
54.00 %
54.00 %
54.00 %
53.96 %
53.95 %
53.93 %
53.91 %
53.86 %
53.83 %
53.78 %
53.77 %
53.74 %
53.66 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.05 %
0.00 %
11.06 %
12.17 %
13.63 %
14.64 %
DIIs
12.41 %
12.32 %
14.76 %
16.03 %
16.67 %
17.52 %
18.08 %
18.54 %
19.08 %
18.65 %
18.58 %
17.97 %
18.38 %
17.62 %
16.81 %
16.41 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.00 %
0.01 %
0.00 %
Public / Retail
20.50 %
19.69 %
17.64 %
18.38 %
17.87 %
17.37 %
16.94 %
16.70 %
15.98 %
15.66 %
15.34 %
15.17 %
14.69 %
14.38 %
13.87 %
13.42 %
Others
11.18 %
12.08 %
11.70 %
11.58 %
11.47 %
11.10 %
11.02 %
10.81 %
11.00 %
11.79 %
2.17 %
13.03 %
2.09 %
2.05 %
1.94 %
1.87 %
No of Share Holders
0
65,715
70,740
71,788
64,861
61,314
60,268
58,629
56,633
55,965
60,817
63,230
63,892
66,953
62,743
62,081

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 5 1 2 5 11 16.5 16.5 17.75 12.25 0.00
Dividend Yield (%) 2.89 0.64 1.1 1.96 1.75 2.1 1.67 1.08 0.75 0.00

Corporate Action

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 201814 hours ago
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 20153 days ago
Noting Of Cautionary Letter Received From The Exchanges3 days ago
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Apr 01, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Apr 01, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 29, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 28, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 18, 2025
USFDA Inspection Of CompanyS API Manufacturing Facility - D9 At Panoli GujaratMar 14, 2025
USFDA Inspection Of CompanyS Manufacturing Facility - T20 At Panoli GujaratMar 08, 2025
DJSI (Dow Jones Sustainable Index) ESG Score ReleaseMar 05, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 27, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 27, 2025
Intimation Of Schedule Of Analysts/Institutional Investors MeetFeb 19, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Integrated Filing (Financial)Feb 04, 2025
Board Comments On Fine Levied By The Exchange For Delayed ComplianceFeb 04, 2025
Intimation Of Record DateFeb 04, 2025
Corporate Action-Board approves DividendFeb 04, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2025
Unaudited Financial Results For The Quarter Ended On December 31 2024Feb 04, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Board Meeting Intimation for (I) Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2024; And (Ii) Consideration Of Declaration Of InterimJan 24, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 24, 2025
PresentationJan 16, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Closure of Trading WindowDec 27, 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 18, 2024
Allotment Of Equity Shares On Exercise Of Stock Options Pursuant To Employee Stock Option Scheme - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Regulations And Disclosure Requirements) Regulations, 2015Dec 06, 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSNov 20, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 07, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 07, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 07, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 07, 2024
Board Comments On Fine Levied By The Exchange For Delayed ComplianceNov 06, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2024
Board Meeting Outcome for Outcome Of Meeting Of Board Of DirectorsNov 06, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 25, 2024
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended On September 30, 2024Oct 25, 2024
3Rd Sustainability (ESG) ReportOct 21, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 21, 2024

Technical Indicators

RSI(14)
Neutral
46.90
ATR(14)
Less Volatile
71.66
STOCH(9,6)
Neutral
38.98
STOCH RSI(14)
Oversold
17.06
MACD(12,26)
Bearish
-4.46
ADX(14)
Strong Trend
25.73
UO(9)
Bearish
61.40
ROC(12)
Downtrend And Accelerating
-6.43
WillR(14)
Neutral
-48.62

About J B Chemicals and Pharmaceuticals

J.B. Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1976. It manufactures and markets a range of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. The company specializes in gastroenterology, hypertension, and dermatology, with additional focus on nephrology, respiratory, virology, diabetes, and nicotine replacement therapy. Key brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has manufacturing facilities in various locations in India and maintains a direct presence in Russia and South Africa, with distributor relationships in the US and other international markets. In 2020, Tau Investment Holdings Pte. Ltd., an affiliate of KKR, acquired a controlling stake in the company. J.B. Chemicals & Pharmaceuticals continues to expand its product portfolio through new launches and acquisitions in various therapeutic segments.
Chairperson NameArun Duggal